Carisma Therapeutics (CARM) Institutional Ownership $0.39 -0.01 (-1.62%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.38 -0.01 (-1.55%) As of 07/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Carisma Therapeutics (NASDAQ:CARM)CurrentInstitutional OwnershipPercentage44.27%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$1.24MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$1.09M Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CARM Institutional Buying and Selling by Quarter Carisma Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/6/2025Universal Beteiligungs und Servicegesellschaft mbH200,000$62K0.0%N/A0.479% 2/17/2025Millennium Management LLC120,157$50K0.0%-15.7%0.288% 2/13/2025Renaissance Technologies LLC231,357$97K0.0%+11.9%0.554% 11/19/2024Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/16/2024Geode Capital Management LLC259,184$254K0.0%-8.5%0.621% 11/15/2024Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/15/2024Wexford Capital LP34,861$34K0.0%+75.5%0.083% 9/16/2024Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024TPG GP A LLC842,031$1.28M0.0%-42.0%2.027% Get the Latest News and Ratings for CARM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2024Renaissance Technologies LLC139,360$212K0.0%-38.3%0.335% 5/10/2024Vanguard Group Inc.1,579,961$3.59M0.0%+0.7%3.803% 5/7/2024Empowered Funds LLC26,984$61K0.0%-43.9%0.065% 2/14/2024Trustees of The University of Pennsylvania1,252,107$3.67M10.3%-28.9%3.102% 10/13/2023SG Americas Securities LLC13,653$58K0.0%N/A0.034% 9/21/2023Barclays PLC5,312$47K0.0%N/A0.013% 8/4/2023American International Group Inc.12,834$113K0.0%N/A0.032% 7/27/2023EA Series Trust40,434$355K0.0%N/A0.100% 6/15/2023Trustees of The University of Pennsylvania2,182,812$6.77M6.6%N/A5.422% 5/15/2023Wittenberg Investment Management Inc.46,703$145K0.1%N/A0.459% 5/12/2023Deuterium Capital Management LLC51,256$159K0.2%N/A0.504% 5/10/2023Connor Clark & Lunn Investment Management Ltd.14,796$46K0.0%N/A0.145% 5/3/2023Jump Financial LLC17,542$54K0.0%N/A0.172% 5/1/2023Virtu Financial LLC15,335$48K0.0%N/A0.151% 4/27/2023Stratos Wealth Partners LTD.19,899$62K0.0%N/A0.195% 4/24/2023 Blodgett Wealth Advisors LLC29,660$92K0.1%N/A0.291% 4/14/2023BML Capital Management LLC411,398$1.28M1.1%N/A4.041% (Data available from 1/1/2016 forward) CARM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CARM shares? During the previous two years, 13 institutional investors and hedge funds held shares of Carisma Therapeutics. The most heavily invested institutionals were Trustees of The University of Pennsylvania ($3.67M), Vanguard Group Inc. ($3.59M), TPG GP A LLC ($1.28M), Barclays PLC ($539K), Geode Capital Management LLC ($254K), American International Group Inc. ($113K), and Renaissance Technologies LLC ($97K).Learn more on Carisma Therapeutics' institutional investors. What percentage of Carisma Therapeutics' stock is owned by institutional investors? 44.27% of Carisma Therapeutics' stock is owned by institutional investors. Learn more on CARM's institutional investor holdings. Which institutional investors have been buying Carisma Therapeutics' stock? The following institutional investors have purchased Carisma Therapeutics' stock in the last 24 months: Barclays PLC ($1.10M), Universal Beteiligungs und Servicegesellschaft mbH ($200K), Point72 Asia Singapore Pte. Ltd. ($52.01K), Renaissance Technologies LLC ($24.60K), Wexford Capital LP ($15K), SG Americas Securities LLC ($13.65K), and American International Group Inc. ($12.83K). How much institutional buying is happening at Carisma Therapeutics? Institutional investors have bought a total of 1,390,192 shares in the last 24 months. This purchase volume represents approximately $1.24M in transactions. Which of Carisma Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Carisma Therapeutics stock in the last 24 months: TPG GP A LLC ($609.85K), Renaissance Technologies LLC ($86.64K), Geode Capital Management LLC ($24.22K), and Millennium Management LLC ($22.37K). How much institutional selling is happening at Carisma Therapeutics? Institutional investors have sold a total of 743,074 shares in the last 24 months. This volume of shares sold represents approximately $1.09M in transactions. Related Companies Evogene Major Shareholders Applied Therapeutics Major Shareholders Repare Therapeutics Major Shareholders CervoMed Major Shareholders Assertio Major Shareholders Sutro Biopharma Major Shareholders Werewolf Therapeutics Major Shareholders Scilex Major Shareholders Ikena Oncology Major Shareholders Barinthus Biotherapeutics Major Shareholders This page (NASDAQ:CARM) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA grave, grave error.Nvidia just hit $4 trillion… but a tech apocalypse may already be underway. A controversial new documentary...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
